The estimated Net Worth of Matthew B. Klein is at least $2.04 Milion dollars as of 14 May 2024. Matthew Klein owns over 17,153 units of PTC Therapeutics Inc stock worth over $949,545 and over the last 5 years he sold PTCT stock worth over $1,089,619. In addition, he makes $0 as Chief Development Officer at PTC Therapeutics Inc.
Sign up
Matthew Klein PTCT stock SEC Form 4 insiders trading
Matthew has made over 14 trades of the PTC Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 17,153 units of PTCT stock worth $553,527 on 14 May 2024.
The largest trade he's ever made was exercising 17,153 units of PTC Therapeutics Inc stock on 14 May 2024 worth over $553,527. On average, Matthew trades about 2,906 units every 56 days since 2020. As of 14 May 2024 he still owns at least 29,425 units of PTC Therapeutics Inc stock.
You can see the complete history of Matthew Klein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Klein biography
Dr. Matthew B. Klein M.D. serves as Chief Development Officer of the Company. Dr. Klein joined the Company in October 2019 as Global Head Gene and Mitochondrial Therapies and became Global Head Clinical Development in March 2020. Prior to joining the Company, Dr. Klein was Chief Executive Officer of BioElectron Technology Corporation (“BioElectron”) from 2018 to 2019, and has served as a board member since 2018. Dr. Klein served as the Chief Medical Officer of BioElectron from 2013 to 2019 and was Senior Vice President, Clinical Science at BioElectron from 2012 to 2013. Dr. Klein has a BA from the University of Pennsylvania, an MD from Yale University School of Medicine and an M.S in epidemiology from the University of Washington School of Public Health.
How old is Matthew Klein?
Matthew Klein is 48, he's been the Chief Development Officer of PTC Therapeutics Inc since 2020. There are 16 older and 3 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
What's Matthew Klein's mailing address?
Matthew's mailing address filed with the SEC is C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100, SOLANA BEACH, CA, 92075.
Insiders trading at PTC Therapeutics Inc
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel oraz Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
What does PTC Therapeutics Inc do?
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
What does PTC Therapeutics Inc's logo look like?
Complete history of Matthew Klein stock trades at PTC Therapeutics Inc i ClearPoint Neuro Inc
PTC Therapeutics Inc executives and stock owners
PTC Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Stuart Peltz,
Chief Executive Officer, Director -
Neil Almstead,
Chief Technical Operations Officer -
Mark Boulding,
Executive Vice President, Chief Legal Officer -
Emily Hill,
Principal Financial Officer, Treasurer -
Dr. Stuart W. Peltz,
Co-Founder, CEO & Exec. Director -
Christine Utter,
Senior Vice President - Finance, Chief Accounting Officer -
Mark Elliott Boulding,
Exec. VP & Chief Legal Officer -
Dr. Neil Almstead,
Chief Technical Operations Officer -
Michael Schmertzler,
Independent Chairman of the Board -
Allan Jacobson,
Independent Director -
Emma Reeve,
Independent Director -
David Southwell,
Independent Director -
Dawn Svoronos,
Independent Director -
Glenn Steele,
Independent Director -
Jerome Zeldis,
Independent Director -
Stephanie Okey,
Independent Director -
Dr. Allan Steven Jacobson,
Independent Co-Founder, Chairman of Scientific Advisory Board & Director -
Eric Pauwels,
Chief Business Officer -
Matthew Klein,
Chief Development Officer -
Jane Baj,
VP of Corp. Communications -
Alex Kane,
Investor Relations Officer -
Ellen Welch Ph.D.,
Chief Scientific Officer -
Christine Utter,
Sr. VP, Chief Accounting Officer & Head of People Services -
Adam Koppel,
Director -
Cameron Geoffrey Mc Donough,
Director -
Tuyen Ong,
Chief Medical Officer -
Marcio Souza,
Chief Operating Officer -
Pharma Holdings Ii, Llc Com...,
10% owner -
Mark Rothera,
Chief Commercial Officer -
Ronald C Jr Renaud,
Director -
Suisse/ Credit,
-
Claudia De Oliveira Ribeiro...,
President -
Bioventures Cayman Ltd Hbm,
10% owner -
Robert J. Spiegel,
Chief Medical Officer -
Richard Aldrich,
Director -
Ventures Inc.Vulcan Capital...,
-
Shane William Charles Kovacs,
EVP, CFO & Head of Corp Dev -
Axel Bolte,
Director -
Michael L Kranda,
Director -
Pierre Gravier,
CHIEF FINANCIAL OFFICER -
Mary L. Smith,
-
William F. Jr. Bell,
-
Alethia Young,
-
Lee Scott Golden,
EVP & CHIEF MEDICAL OFFICER